Pacira BioSciences, Inc. (PCRX) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Pacira BioSciences, Inc. (PCRX) Healthcare & Pipeline Overview

Pacira BioSciences, Inc. (PCRX) is a healthcare company specializing in non-opioid pain management and regenerative health solutions. Their portfolio includes EXPAREL, ZILRETTA, and iovera, offering alternatives to traditional opioid-based pain relief within the specialty pharmaceutical market, addressing the growing demand for non-addictive pain treatments.

What Is the Investment Thesis for PCRX?

The increasing awareness of opioid addiction and the demand for safer alternatives drive the adoption of Pacira's products, particularly EXPAREL and ZILRETTA. With a gross margin of 77.4%, the company demonstrates strong profitability in its core product lines. Key growth catalysts include the expansion of EXPAREL's applications into new surgical procedures and the continued adoption of ZILRETTA for osteoarthritis knee pain. The company's focus on regenerative health solutions further diversifies its revenue streams and positions it for long-term growth. However, potential risks include competition from other pain management therapies and regulatory challenges related to drug approvals and market access. Pacira's P/E ratio of 71.46 reflects investor expectations of future growth, but also indicates a premium valuation.

Based on FMP financials and quantitative analysis

PCRX Key Highlights

Market Cap of $990M indicates Pacira BioSciences' current valuation in the market.

• Gross Margin of 77.4% reflects strong profitability in its core product lines.
• P/E Ratio of 71.46 suggests a premium valuation, reflecting investor expectations of future growth.
• Beta of 0.20 indicates low volatility compared to the overall market, suggesting a relatively stable investment.
• Profit Margin of 0.7% indicates room for improvement in net profitability as the company scales.

Who Are PCRX's Competitors?

PCRX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are PCRX's Key Strengths?

Innovative non-opioid pain management solutions.

• Proprietary drug delivery technology (MVL).
• Established market presence with EXPAREL and ZILRETTA.
• Strong gross margins.

What Are PCRX's Weaknesses?

High P/E ratio indicates premium valuation.

• Limited product portfolio compared to larger pharmaceutical companies.
• Reliance on a few key products for revenue generation.
• Relatively low profit margin.

What Could Drive PCRX Stock Higher?

Expansion of EXPAREL's use into new surgical procedures, driving increased revenue.

• Continued adoption of ZILRETTA for osteoarthritis knee pain, fueled by an aging population.
• Potential regulatory approvals for new regenerative health solutions, diversifying the product portfolio.
• Strategic acquisitions and partnerships to expand product offerings and market reach.

What Are the Key Risks for PCRX?

Rich valuation — a P/E of 71.46 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.

• Competition from other pain management therapies, including generic alternatives.
• Regulatory challenges related to drug approvals and market access, delaying product launches.
• Changes in healthcare reimbursement policies, impacting product pricing and market access.
• Product liability claims related to the use of Pacira's products, affecting the company's reputation and financial performance.

What Are the Growth Opportunities for PCRX?

• Expansion of EXPAREL into New Surgical Procedures: EXPAREL, Pacira's flagship product, has the potential to expand its applications into a wider range of surgical procedures. The market for post-surgical pain management is substantial, with a growing demand for non-opioid alternatives. By securing approvals for use in additional procedures, Pacira can significantly increase EXPAREL's market penetration. This expansion is expected to contribute to revenue growth within the next 2-3 years, capitalizing on the trend towards opioid-sparing pain management protocols.
• Increased Adoption of ZILRETTA for Osteoarthritis Knee Pain: ZILRETTA, a non-opioid injectable for osteoarthritis knee pain, represents a significant growth opportunity. The prevalence of osteoarthritis is increasing, driven by an aging population and rising obesity rates. By increasing awareness of ZILRETTA's benefits and expanding its market reach, Pacira can capture a larger share of the osteoarthritis pain management market. This growth is anticipated over the next 3-5 years, aligning with demographic trends and the growing demand for non-opioid pain relief options.
• Development and Commercialization of New Regenerative Health Solutions: Pacira's focus on regenerative health solutions represents a long-term growth opportunity. By developing and commercializing innovative regenerative therapies, the company can diversify its revenue streams and address unmet needs in areas such as wound healing and tissue regeneration. This expansion is expected to contribute to revenue growth over the next 5-7 years, as regenerative medicine gains wider acceptance and clinical applications.
• Geographic Expansion into International Markets: Pacira BioSciences currently operates primarily in the United States. Expanding into international markets, such as Europe and Asia, represents a significant growth opportunity. By securing regulatory approvals and establishing distribution networks in these regions, Pacira can tap into new sources of revenue and diversify its geographic footprint. This expansion is anticipated over the next 3-5 years, aligning with the global trend towards non-opioid pain management.
• Strategic Acquisitions and Partnerships to Expand Product Portfolio: Pacira can pursue strategic acquisitions and partnerships to expand its product portfolio and gain access to new technologies and markets. By acquiring companies with complementary products or technologies, Pacira can strengthen its position in the pain management and regenerative health markets. These acquisitions and partnerships are expected to contribute to revenue growth and market share gains over the next 2-3 years, enhancing Pacira's competitive advantage.

What Are PCRX's Competitive Advantages?

• Proprietary multivesicular liposome (MVL) technology provides a competitive advantage in drug delivery.
• Established market presence and brand recognition for EXPAREL and ZILRETTA.
• Strong relationships with healthcare providers and key opinion leaders.
• Focus on non-opioid pain management aligns with growing demand for safer alternatives.

What Does PCRX Do?

Pacira BioSciences, Inc., founded in 2006 and headquartered in Tampa, Florida, is dedicated to providing non-opioid pain management and regenerative health solutions. Originally named Pacira Pharmaceuticals, Inc., the company rebranded in April 2019 to Pacira BioSciences, Inc., reflecting its broader focus on biological solutions. The company's core mission is to offer alternatives to traditional opioid-based pain relief, addressing the growing concerns around opioid addiction and related side effects. Pacira's flagship product is EXPAREL, a bupivacaine liposome injectable suspension designed to provide long-lasting pain relief after surgery. Other key products include ZILRETTA, a triamcinolone acetonide extended-release injectable suspension for osteoarthritis knee pain, and the iovera system, a handheld cryoanalgesia device that uses targeted cold therapy to relieve pain by temporarily blocking nerve signals. Pacira also develops proprietary multivesicular liposome (MVL) technology, a drug delivery system that encapsulates drugs to control their release and improve their efficacy. Pacira BioSciences operates primarily in the United States, serving healthcare practitioners and their patients with innovative pain management solutions. By focusing on non-opioid alternatives, Pacira aims to improve patient outcomes and reduce the reliance on potentially addictive pain medications.

What Products and Services Does PCRX Offer?

• Develops and commercializes non-opioid pain management solutions.
• Offers EXPAREL, a long-lasting, local analgesia for post-surgical pain.
• Provides ZILRETTA, an extended-release injectable for osteoarthritis knee pain.
• Offers the iovera system, a cryoanalgesia device for targeted nerve pain relief.
• Focuses on reducing the reliance on opioid-based pain medications.
• Utilizes proprietary multivesicular liposome (MVL) technology for drug delivery.
• Serves healthcare practitioners and patients in the United States.

How Does PCRX Make Money?

• Develops and manufactures non-opioid pain management products.
• Sells products directly to hospitals, surgery centers, and physicians.
• Generates revenue through product sales and licensing agreements.
• Invests in research and development to expand its product portfolio.

What Industry Does PCRX Operate In?

Pacira BioSciences operates within the specialty pharmaceutical segment of the healthcare industry, which is experiencing growth driven by the demand for innovative pain management solutions. The increasing awareness of opioid addiction has created a significant market opportunity for non-opioid alternatives. The competitive landscape includes companies offering both pharmaceutical and device-based pain management therapies. Pacira differentiates itself through its focus on long-lasting, non-opioid solutions like EXPAREL and ZILRETTA. The market for pain management is expected to continue growing, driven by an aging population and the increasing prevalence of chronic pain conditions.

Who Are PCRX's Key Customers?

• Hospitals and surgery centers seeking non-opioid pain management options.
• Physicians and healthcare providers treating post-surgical pain.
• Patients seeking alternatives to opioid-based pain relief.
• Specialists treating osteoarthritis knee pain.

Over the past six months, Pacira BioSciences, Inc. insiders filed 34 SEC Form 4 transactions — 15 sales and 19 purchases. On net that is roughly 92K shares acquired (about $1.1M) — insiders putting money in tends to read as conviction.

Quarterly Financial Performance: Pacira BioSciences, Inc.

Revenue for Pacira BioSciences, Inc. came in at $192.4M during Q2 FY2026, a 8.5% improvement versus the preceding quarter. The company recorded net income of $4.7M, with diluted EPS of $0.12. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, PCRX averaged $0.09 in diluted EPS.

PCRX Valuation & Market Position

With a $990M market cap, Pacira BioSciences, Inc. sits in the small-cap segment of the market. Analyst price targets span from $25.00 to $32.00, with a consensus of $28.75. At the current price of $25.16, that implies approximately 14% upside potential. Relative to its peer group, PCRX's quantitative score of 87/100 is above the peer average of 68/100.

Return on equity for Pacira BioSciences, Inc. stands at 2.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 1.2%, showing how much profit it generates from its asset base. PCRX trades at a trailing price-to-earnings ratio of 71.46, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 17.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.04 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 1.4%, the inverse of the P/E and a quick read on earnings relative to price.

Pacira BioSciences, Inc.'s Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 2.01 places it in the grey zone, a middle ground that warrants monitoring.

Pacira BioSciences, Inc. has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 3.0% above estimates on average.

Company Profile

Pacira BioSciences, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Brisbane, US. The company is led by CEO Frank D. Lee. PCRX has traded publicly since 2011.

PCRX Financials

PCRX Latest News

PCRX Analyst Consensus

PCRX MoonshotScore

Pacira BioSciences, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources